Desideratum for evidence based epidemiology (Q38156063)

29 August 2017

title

Desideratum for evidence based epidemiology (English)

1 reference

29 August 2017

1 reference

3

Martijn J Schuemie

0 references

J. Marc Overhage

series ordinal

1

object named as

J Marc Overhage

1 reference

29 August 2017

Patrick B Ryan

2

1 reference

29 August 2017

Martijn J Schuemie

series ordinal

3

1 reference

29 August 2017

Paul E Stang

series ordinal

4

1 reference

29 August 2017

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

36 Suppl 1

1 reference

29 August 2017

page(s)

S5-14

1 reference

Deming, data and observational studies

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Randomized, controlled trials, observational studies, and the hierarchy of research designs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

A comparison of observational studies and randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Methodological quality and homogeneity influenced agreement between randomized trials and nonrandomized studies of the same intervention for back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Randomized Trials Built on Sand: Examples from COPD, Hormone Therapy, and Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Estrogen plus progestin and the risk of coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

HMG-CoA reductase inhibitors and the risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Use of statins and risk of fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

External validity of randomised controlled trials: "to whom do the results of this trial apply?".

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Factors that can affect the external validity of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Design considerations in an active medical product safety monitoring system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Evaluating the impact of database heterogeneity on observational study results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Prespecified falsification end points: can they validate true observational associations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Validation of a common data model for active safety surveillance research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Evaluation of alternative standardized terminologies for medical conditions within a network of observational healthcare databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Empirical performance of a new user cohort method: lessons for developing a risk identification and analysis system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Empirical performance of a self-controlled cohort method: lessons for developing a risk identification and analysis system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Empirical performance of the calibrated self-controlled cohort analysis within temporal pattern discovery: lessons for developing a risk identification and analysis system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Electronic healthcare databases for active drug safety surveillance: is there enough leverage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Managing data quality for a drug safety surveillance system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Defining a reference set to support methodological research in drug safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Measuring classifier performance: a coherent alternative to the area under the ROC curve

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Reanalysis of two studies with contrasting results on the association between statin use and fracture risk: the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Postmenopausal Estrogen and Progestin Use and the Risk of Cardiovascular Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40264-013-0102-2

Statisticians set sights on observational studies

21 January 2018

1 reference

12 December 2020

Alternative outcome definitions and their effect on the performance of methods for observational outcome studies

1 reference

12 December 2020

Interpreting observational studies: why empirical calibration is needed to correct p-values

1 reference

12 December 2020

The impact of drug and outcome prevalence on the feasibility and performance of analytical methods for a risk identification and analysis system

1 reference

12 December 2020

Postmenopausal estrogen use, cigarette smoking, and cardiovascular morbidity in women over 50. The Framingham Study

1 reference

12 December 2020

Evaluation of disproportionality safety signaling applied to healthcare databases.

1 reference

12 December 2020

Empirical performance of the case-control method: lessons for developing a risk identification and analysis system

1 reference

12 December 2020

Evaluating performance of risk identification methods through a large-scale simulation of observational data

1 reference

12 December 2020

A systematic review of comparisons of effect sizes derived from randomised and non-randomised studies

1 reference

12 December 2020

In defense of pharmacoepidemiology--embracing the yin and yang of drug research

1 reference

12 December 2020

How well do various health outcome definitions identify appropriate cases in observational studies?

1 reference

12 December 2020

Variation in choice of study design: findings from the Epidemiology Design Decision Inventory and Evaluation (EDDIE) survey

1 reference

12 December 2020

Replication of the OMOP experiment in Europe: evaluating methods for risk identification in electronic health record databases

1 reference

12 December 2020

Empirical performance of LGPS and LEOPARD: lessons for developing a risk identification and analysis system.

1 reference

12 December 2020

10.1007/S40264-013-0102-2

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1000623292

0 references

1 reference